Would treating cancer more like a long-term illness extend lives?

A lot of the focus in the medical approach to cancer focuses on destroying it, but what if it was treated cancer like long-term diseases such as diabetes? Researchers have explored the concept of a method to control cancer with a drug delivery system that keeps the cells from multiplying.

The method, which researchers have called the "metronomic dosage regimen," involves giving the patient lower doses of chemotherapy more frequently to create an environment where cancer cells cannot grow.

"This new system takes some existing cancer therapy drugs for ovarian cancer, delivers both of them at the same time and allows them to work synergistically," said Adam Alani, an associate professor in the Oregon State University/Oregon Health & Science University College of Pharmacy, and lead author on the study published in the journal Chemistry of Materials. "Imagine if we could manage cancer on a long-term basis as a chronic condition, like we now do high blood pressure or diabetes. This could be a huge leap forward."

Although still being tested in trials, the method has the potential to leave patients in total remission. Most effective in the most complex cancers including ovarian, sarcoma, breast, prostate and lung, this method could extend the timelines for those give those with months to live by managing the cancer.

In an example of a patient with ovarian cancer, the researchers used the method to administer two chemotherapy drugs at levels between 1/10th and 1/3rd of the maximum tolerable dose. While one drug stops the forming of cancer cells, the other cuts off the blood supply the cells need to survive.

"Our goal is to significantly reduce tumors, slow or stop their regrowth, and allow a person's body and immune system time to recover its health and natural abilities to fight cancer," Alani said. "I'm very optimistic this is possible, and that it could provide an entirely new approach to cancer treatment."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.